#South Korea #Yongin #Medical AI #Sustainability Report #Ltd. #Noul Co.

Noul's Vision for Sustainable Growth: 2024-2025 Sustainability Report

Noul Co., Ltd., a leading medical AI firm focused on blood and cancer diagnostics, recently released its fifth sustainability report for the period of 2024-2025. The comprehensive report highlights Noul's dedication to transparency and responsibility in its business practices, as the company marks a critical transition into a new decade of growth and enhanced corporate value under the leadership of CEO David Lim.

A Transition to Growth

As highlighted by Lim, the year 2024 not only marks the conclusion of Noul's first ten years dedicated to technology development but also signifies the commencement of a period aimed at maximizing business performance and enhancing corporate valuation. With solid sustainability initiatives laid down in prior years, Noul is now poised to leverage these foundations for substantial growth. The focus will be directed at boosting product competitiveness while continuing robust investments in research and development specifically within cancer diagnostics.

Key Highlights from the Report

The sustainability report provides crucial insights into various strategic initiatives Emphasized by Noul’s commitment to innovation and market expansion. Noteworthy highlights include:

• - Global Supply Agreements: The company has successfully signed global supply agreements and ventured into public procurement sectors across significant markets in Europe and Asia.
• - Regulatory Approvals: Noul has secured regulatory approvals in key regions, including Saudi Arabia, to facilitate its operational capacity.
• - WHO and UNITAID Collaboration: A crucial recommendation from a WHO–UNITAID technical report supports Noul's cervical cancer solution as a pivotal advancement in global healthcare.
• - Corporate Value-Up Program: Noul is recognized as the first technology-special company to participate in Korea’s Corporate Value-Up Program, affirming its commitment to sustainable business practices.
• - Scientific Contribution: Collaboration with Labcorp, the largest diagnostic laboratory in the U.S., led to a co-authored publication featured in an international peer-reviewed journal.

Stakeholder Engagement and Transparency

In response to stakeholder inquiries, the report reveals detailed insights into Noul’s strategic initiatives, including:

• - Market Expansion and Quality Assurance for the miLab™ platform.
• - Competitive Edge and scalability details concerning the miLab™ Cartridge, specifically designed for cervical cancer screening.
• - Efforts to enhance diagnostic accessibility across diverse populations.
• - Frameworks for measuring the impact of its initiatives.
• - Plans for environmentally responsible product packaging to reduce environmental footprints.

Noul has committed itself to five 'Sustainability Focus Areas' that add structure to its commitment to ESG (Environmental, Social, and Governance) criteria. These are:
1. Improving Access to Healthcare
2. Compliance, Ethics, and Risk Management
3. Sustainable Governance Practices
4. Fostering a Responsible and Inclusive Workplace
5. Protecting the Planet

For each focus area, mid- to long-term improvement plans are detailed, reflecting the company’s ongoing efforts to foster stakeholder trust and enhance information accessibility.

Commitment to Reliable Reporting

Third-party assurances have been conducted for greenhouse gas emission data, reinforcing Noul's commitment to environmental accountability. According to Justin Ahn, Chief Sustainability Officer, the company actively evaluates stakeholder expectations to align improvements with global standards. Its 2024-2025 sustainability report is crafted adhering to the Global Reporting Initiative (GRI) Standards, which establishes a globally recognized framework for sustainability disclosures.

The complete sustainability report can be accessed on Noul's official website and through the Korean Financial Supervisory Service's disclosure system, demonstrating Noul's commitment to open communication with all stakeholders, including customers, partners, investors, employees, and governmental entities.

Noul aims to revolutionize healthcare by leveraging AI technologies that address global health challenges, ultimately striving to impact the lives of over a billion people by making diagnostic tests more accessible and efficient. For further information, please visit Noul's Website.

About Noul Co., Ltd.

Founded in December 2015, Noul (376930.KQ) has emerged as a pioneering force in AI-powered healthcare solutions. The company has developed the miLab™, globally recognized for its innovative approach in diagnostic testing, aiming to provide essential healthcare solutions, particularly in resource-limited settings. With its cutting-edge technology, Noul is set to make significant advancements in the fields of blood testing and cancer diagnostics, reinforcing its mission to enhance global health outcomes.